0000950170-24-001210.txt : 20240103
0000950170-24-001210.hdr.sgml : 20240103
20240103173550
ACCESSION NUMBER: 0000950170-24-001210
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sepp-Lorenzino Laura
CENTRAL INDEX KEY: 0001777421
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 24508388
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS, INC.
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-01-01
0001652130
Intellia Therapeutics, Inc.
NTLA
0001777421
Sepp-Lorenzino Laura
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
false
true
false
false
EVP, Chief Scientific Officer
false
Common Stock
2024-01-01
4
M
false
3500
A
51734
D
Restricted Stock Unit
2024-01-01
4
M
false
3500
0
D
2024-01-01
2031-03-02
Common Stock
3500
3500
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively.
On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
James Basta, attorney-in-fact
2024-01-03